We explored the prognostic impact of baseline immune markers in cervical cancer and found CD8+ T cell infiltration as the most promising candidate to be associated with beneficial clinical outcome regardless of neoadjuvant treatment (Supplementary Fig. 3a). The gene discussed is CD8A; the disease is cervical cancer.